中文

← All funding rounds

Superluminal Medicines

United StatesDrug discoveryBoston, United StatesPrivate

Website · superluminalrx.com ↗

Designs small-molecule drugs for G protein-coupled receptors (GPCRs) with machine learning, structural biology and its own data: cryo-EM, GPCR co-folding models, de novo design and predicted ADME and toxicity. Its lead programme is an MC4R agonist for rare genetic and hypothalamic obesity.

Disclosed total$93M
Rounds on record2
Latest round$60MSeries B · 2026-09-05
Last stated valuationNone stated
Investors named10
Research on recordNone yet

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date202420252026$33M$60M
Closed round

No research by this company is on the record yet.

Rounds and research, on one timeline

  1. 2026-09-05Series B
    Round

    $60M

    For: take its lead MC4R obesity programme into a Phase 1 trial expected by the end of 2026, and expand its AI-enabled discovery platform

    Toward the clinicModels and platform

    Pulse 2.0 carries the announcement's wording and quotes from the CEO, BVF and RA Capital; the company's own release and site could not be read (403). Described as oversubscribed. Valuation not disclosed.

    Lead · BVF PartnersDeep Track CapitalPerceptive AdvisorsExisting investor · RA Capital ManagementExisting investor · Insight PartnersExisting investor · NVIDIAExisting investor · Catalio Capital ManagementExisting investor · Eli Lilly and CompanyExisting investor · CooleyExisting investor · Gaingels

    On the deal: Harsha Paladugu (Investment Analyst; member of the board, BVF Partners, joins the board); Nandita Shangari (Managing Director; member of the board, RA Capital Management, joins the board)

    Reported by Pulse 2.0 · pulse2.com ↗On the timeline →

  2. 2023-08-28Seed
    Round

    $33M

    For: progress its small-molecule pipeline, first aimed at GPCR targets

    Toward the clinicModels and platform

    The GlobeNewswire release as reposted by Insight Partners calls it a funding round; Insight's title and BioPharma Dive call it a seed. Founders' backgrounds from BioPharma Dive (https://www.biopharmadive.com/news/superluminal-nvidia-gpcr-biotech-seed-funding/692028/).

    Lead · RA Capital ManagementInsight PartnersNVIDIAGaingels

    On the deal: Andrew Levin (Partner and Managing Director; board member, RA Capital Management, joins the board); Dylan Morris (Managing Director; board member, Insight Partners, joins the board)

    Announced by the company · insightpartners.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.